Literature DB >> 1871691

Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease.

L B Palmer1, H E Greenberg, M J Schiff.   

Abstract

Invasive pulmonary aspergillosis usually occurs in severely immunocompromised or neutropenic patients. Six patients with invasive aspergillosis are described whose only defence impairment was underlying lung disease and corticosteroid treatment. Cough, fever, and sputum production were the usual reasons for presentation and four patients developed the sepsis syndrome. Radiographic findings included de novo cavitation in three patients and rapid radiographic progression in four. Aspergillus species were isolated from respiratory secretions of all patients early in the course of the disease. Treatment was effective in only two patients and the subsequent progress of the others was consistent with a chronic necrotising process. Invasive pulmonary aspergillosis is uncommon in patients with respiratory diseases receiving corticosteroids, but should be considered when pneumonia and cavitary infiltrates occur.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1871691      PMCID: PMC1020907          DOI: 10.1136/thx.46.1.15

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  38 in total

1.  Clinical and immunologic significance of Aspergillus fumigatus in the sputum.

Authors:  J PEPYS; R W RIDDELL; K M CITRON; Y M CLAYTON; E I SHORT
Journal:  Am Rev Respir Dis       Date:  1959-08

2.  Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year prospective study.

Authors:  V L Yu; R R Muder; A Poorsattar
Journal:  Am J Med       Date:  1986-08       Impact factor: 4.965

3.  Serious infectious complications of corticosteroid therapy for COPD.

Authors:  P M Wiest; T Flanigan; R A Salata; D M Shlaes; M Katzman; M M Lederman
Journal:  Chest       Date:  1989-06       Impact factor: 9.410

4.  Invasive pulmonary aspergillosis in nonimmunocompromised, nonneutropenic hosts.

Authors:  G H Karam; F M Griffin
Journal:  Rev Infect Dis       Date:  1986 May-Jun

5.  Disseminated Strongyloides stercoralis and Aspergillus fumigatus presenting as diffuse interstitial pneumonitis in a steroid-dependent chronic obstructive pulmonary disease patient.

Authors:  L Tankanow; M S Eichenhorn
Journal:  Henry Ford Hosp Med J       Date:  1988

6.  Rapidly progressive pneumonia in a patient with chronic obstructive pulmonary disease.

Authors:  L B Palmer; M J Schiff
Journal:  Chest       Date:  1989-01       Impact factor: 9.410

7.  Pulmonary berylliosis on corticosteroid therapy, with cavitating lung lesions and aspergillomata--report on a fatal case.

Authors:  A A O'Brien; D P Moore; J A Keogh
Journal:  Postgrad Med J       Date:  1987-09       Impact factor: 2.401

8.  In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus.

Authors:  A R Waldorf; S M Levitz; R D Diamond
Journal:  J Infect Dis       Date:  1984-11       Impact factor: 5.226

9.  [Disseminated invasive aspergillosis associated with Mycoplasma pneumoniae infection].

Authors:  J Ordronneau; A Y de Lajartre; S Chollet; P Germaud; D Moinard; E Chailleux
Journal:  Rev Mal Respir       Date:  1987       Impact factor: 0.622

10.  Therapeutic concentrations of glucocorticoids suppress the antimicrobial activity of human macrophages without impairing their responsiveness to gamma interferon.

Authors:  A Schaffner
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

View more
  24 in total

Review 1.  A persistent challenge: the diagnosis of respiratory disease in the non-AIDS immunocompromised host.

Authors:  C Mayaud; J Cadranel
Journal:  Thorax       Date:  2000-06       Impact factor: 9.139

2.  DISSEMINATED ASPERGILLOSIS IN AN IMMUNOCOMPETENT HOST WITH PREDISPOSING RISK FACTORS: A Case Report.

Authors:  Deepak Rosha; B N Panda; G S Chopra; P Joshi
Journal:  Med J Armed Forces India       Date:  2017-06-26

3.  Aspergilloma in a patient with a history of TB.

Authors:  Henna Singh
Journal:  BMJ Case Rep       Date:  2014-03-07

Review 4.  Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients.

Authors:  J Beyer; S Schwartz; V Heinemann; W Siegert
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 5.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

6.  Th1 and Th2 cytokines in mice with invasive aspergillosis.

Authors:  E Cenci; S Perito; K H Enssle; P Mosci; J P Latgé; L Romani; F Bistoni
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

7.  Human dendritic cells following Aspergillus fumigatus infection express the CCR7 receptor and a differential pattern of interleukin-12 (IL-12), IL-23, and IL-27 cytokines, which lead to a Th1 response.

Authors:  Valérie Gafa; Roberto Lande; Maria Cristina Gagliardi; Martina Severa; Elena Giacomini; Maria Elena Remoli; Roberto Nisini; Carlo Ramoni; Paolo Di Francesco; Delphine Aldebert; Renée Grillot; Eliana M Coccia
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

8.  Challenges in prevention, diagnosis and therapy of emerging fungal diseases. Aspergillosis: A case study.

Authors:  P U Sarma; P V Sarma; T Madan
Journal:  Indian J Clin Biochem       Date:  2000-08

9.  Polymorphisms within the ARNT2 and CX3CR1 Genes Are Associated with the Risk of Developing Invasive Aspergillosis.

Authors:  M Jurado; J Sainz; C B Lupiañez; M Martínez-Bueno; J M Sánchez-Maldonado; J Badiola; C Cunha; J Springer; M Lackner; J Segura-Catena; L M Canet; L Alcazar-Fuoli; M A López-Nevot; L Fianchi; J M Aguado; L Pagano; E López-Fernández; M Alarcón-Riquelme; L Potenza; S M Gonçalves; M Luppi; L Moratalla; C Solano; A Sampedro; P González-Sierra; M Cuenca-Estrella; K Lagrou; J A Maertens; C Lass-Flörl; H Einsele; L Vazquez; J Loeffler; R Ríos-Tamayo; A Carvalho
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

10.  Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis.

Authors:  Christopher R Sudfeld; Elliott C Dasenbrook; William G Merz; Karen C Carroll; Michael P Boyle
Journal:  J Cyst Fibros       Date:  2009-12-31       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.